Interaction of gadolinium-based MR contrast agents with choline: Implications for MR spectroscopy (MRS) of the breast

Magnetic Resonance in Medicine

Volumn 61, Issue 6, 2009, Pages 1286-1292

  Lenkinski, Robert E ^a,b   Wang, Xiaoen ^a   Elian, Mostafa ^a   Goldberg, S Nahum ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Breast MRS; Choline; Contrast agents; In vivo; Interactions

Indexed keywords

BEAM PLASMA INTERACTIONS; CHELATION; DISEASES; GADOLINIUM; MAGNETIC RESONANCE SPECTROSCOPY; PHANTOMS;

BREAST MRS; CHOLINE; CONTRAST AGENT; HUMAN BREAST CANCER; IN-VIVO; MAGNETIC RESONANCE SPECTROSCOPIES (MRS); NEGATIVELY CHARGED; SPECTROSCOPIC DETECTION;

MAGNETIC RESONANCE;

CHOLINE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CHEMICAL STRUCTURE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; IMAGING SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHANTOM; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REPRODUCIBILITY;

EID: 67049109436     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21937     Document Type: Article

References (44)

1. Liberman L. Breast cancer screening with MRI - what are the data for patients at high risk? N Engl J Med 2004;351:497-500.
2. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007;43:1905-1917. (Pubitemid 47299201)
3. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-679. (Pubitemid 351669112)
4. Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis, and staging. Oncology (Williston Park) 2007;21:1521-1528. (Pubitemid 350252939)
5. Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology 2007;244:672-691.
6. Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007;45:863-880. (Pubitemid 47410063)
7. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
8. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [Erratum]. CA Cancer J Clin 2007;57:185. (Pubitemid 46535708)
9. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res 2005;7:149-152. (Pubitemid 40872777)
10. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-1203. (Pubitemid 34993869)
11. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001;3:36-40. (Pubitemid 32223651)
12. Sharma U, Sharma R, Jagannathan NR. Characterization of breast lesions by magnetic resonance imaging (MRI) and spectroscopy (MRS). Curr Med Imaging Rev 2006;2:329-340. (Pubitemid 44194417)
13. Tse GM, Yeung DKY, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 2007;104:249-255.
14. Joe BN, Chen VY, Salibi N, Fuangtharntip P, Hildebolt CF, Bae KT. Evaluation of 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. Invest Radiol 2005;40:405-411. (Pubitemid 40863783)
15. Murphy PS, Leach MO, Rowland IJ. Signal modulation in H-1 magnetic resonance spectroscopy using contrast agents: proton relaxivities of choline, creatine, and N-acetylaspartate. Magn Reson Med 1999;42:1155-1158.
16. Murphy PS, Leach MO, Rowland IJ. The effects of paramagnetic contrast agents on metabolite protons in aqueous solution. Phys Med Biol 2002;47:N53-N59. (Pubitemid 34269542)
17. Lin AP, Ross BD. Short-echo time proton MR spectroscopy in the presence of gadolinium. J Comput Assist Tomogr 2001;25:705-712. (Pubitemid 32861693)
18. Murphy PS, Dzik-Jurasz ASK, Leach MO, Rowland IJ. The effect of Gd-DTPA on T-1-weighted choline signal in human brain tumours. Magn Reson Imaging 2002;20:127-130. (Pubitemid 34309140)
19. Sijens PE, Oudkerk M, van Dijk P, Levendag PC, Vecht CJ. H-1 MR spectroscopy monitoring of changes in choline peak area and line shape after Gd-contrast administration. Magn Reson Imaging 1998;16:1273-1280. (Pubitemid 29019553)
20. Sijens PE, VandenBent MJ, VanDijk P, Oudkerk M. Chemical shift imaging reveals loss of brain tumor choline signal after administration of a gadolinium contrast agent. Radiology 1996;201:11-111
21. Sijens PE, van den Bent MJ, Nowak PJ, van Dijk P, Oudkerk M. 1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med 1997;37:222-225. (Pubitemid 27045394)
22. Smith JK, Kwock L, Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR Am J Neuroradiol 2000;21:1084-1089. (Pubitemid 30390548)
23. Elgavish GA, Reuben J. Aqueous lanthanide shift-reagents. 3. Interaction of ethylenediaminetetraacetate chelates with substituted ammonium cations. J Am Chem Soc 1977;99:1762-1765.
24. Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, Torchillin VP, Halpern EF, Kruskal JB. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002;222:797-804. (Pubitemid 34215233)
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310. (Pubitemid 16134762)
26. Bloembergen N. Proton relaxation times in paramagnetic solutions. J Chem Phys 1957;27:572-573.
27. Lenkinski RE, Reuben J. Line broadenings induced by lanthanide shift-reagents - concentration, frequency, and temperature effects. J Magn Reson 1976;21:47-56.
28. Solomon I. Relaxation processes in a system of 2 spins. Phys Rev 1955;99:559-565.
29. Lenkinski RE. Lanthanide complexes of peptides and proteins. In: Berliner LJ, Reuben J, editors. Biological magnetic resonance. New York: Plenum Press; 1984. p 23-71.
30. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99:2293-2352. (Pubitemid 30498114)
31. Lenkinski RE, Reuben J. Multisite model for lanthanide shift-reagent coordination to monofunctional substrates -effects of rotational and site averaging on shifts and relaxation rates. J Am Chem Soc 1976;98:4065-4068.
32. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-84. (Pubitemid 29062961)
33. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007;120:1721-1730. (Pubitemid 46402874)
34. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res 1996;16:1375-1379. (Pubitemid 26257805)
35. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002;62:1966-1970. (Pubitemid 34408439)
36. Blusztajn JK. Developmental neuroscience: choline, a vital amine. Science 1998;281:794-795.
37. Zeisel SH, Dacosta KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF, Beiser A. Choline, an essential nutrient for humans. FASEB J 1991;5:2093-2098. (Pubitemid 121000174)
38. Savendahl L, Mar MH, Underwood LE, Zeisel SH. Prolonged fasting in humans results in diminished plasma choline concentrations but does not cause liver dysfunction. Am J Clin Nutr 1997;66:622-625. (Pubitemid 27366787)
39. Zeisel SH, Growdon JH, Wurtman RJ, Magil SG, Logue M. Normal plasma choline responses to ingested lecithin. Neurology 1980;30:1226-1229. (Pubitemid 11238254)
40. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch 2004;447:666-676. (Pubitemid 38241452)
41. Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Rev Physiol Biochem Pharmacol 2003;150:36-90.
42. Vance JE, Vance DE. Phospholipid biosynthesis in mammalian cells. Biochem Cell Biol 2004;82:113-128.
43. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006;19:30-40. (Pubitemid 43250787)
44. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002;15:327-337. (Pubitemid 34960100)